|
|
|
|
Assessment of Peripheral Blood and Bone Marrow Cells Apoptosis Caused by Purine Analogues in Patients with Chronic Lymphocytic Leukemia in Correlation with Parameters of Disease Progression
_ Assessment of Peripheral Blood and Bone Marrow Cells Apoptosis Caused by Purine Analogues in Patients with Chronic Lymphocytic Leukemia in Correlation with Parameters of Disease Progression.
|
|
|
NICE Set To Recommend Rituximab For Relapsed Or Refractory Chronic Lymphocytic Leukaemia
The National Institute for Health and Clinical Excellence (NICE) has today (4 March) issued final draft guidance recommending the drug rituximab(MabThera) as a treatment for certain patients with relapsed or refractory chronic lymphocytic leukaemia.
|
|
|
Medical News: NICE Set To Recommend Rituximab For Relapsed Or Refractory Chronic Lymphocytic Leukaemia
The National Institute for Health and Clinical Excellence (NICE) has today (4 March) issued final draft guidance recommending the drug rituximab(MabThera) as a treatment for certain patients with relapsed or refractory chronic lymphocytic leukaemia.
|
|
|
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia [Hematolo
William G.Wierda,* Thomas J. Kipps, Ji Mayer, Stephan Stilgenbauer, Cathy D. Williams, Andrzej Hellmann, Tadeusz Robak, Richard R. Furman, Peter Hillmen, Marek Trneny, Martin J.S. Dyer, Swami Padmanabhan, Magdalena Piotrowska, Tomas Kozak, Geoffrey...
Journal of Clinical Oncology:
Mar 3 2010 12:50AM
Matching: leukemia lymphocytic chronic
|
Find similar documents
|
|
|
|
Rituxan Approved for Chronic Lymphocytic Leukemia
The U.S.Food and Drug Administration (FDA) has expanded the approval of Rituxan (rituximab) to include the treatment of certain patients with chronic lymphocytic leukemia. Chronic lymphocytic leukemia (CLL) is the most common adult ...
|
|
|
FDA Approves Rituxan for Chronic Lymphocytic Leukemia
_ FDA Approves Rituxan for Chronic Lymphocytic Leukemia.
|
|
|
FDA Expands Use Of Rituxan For Chronic Lymphocytic Leukemia (DJ)
FDA Expands Use Of Rituxan For Chronic Lymphocytic Leukemia By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The Food and Drug Administration Thursday expanded the approval of the drug Rituxan to treat certain...
|
|
|
FDA Expands Use Of Rituxan For Chronic Lymphocytic Leukemia
By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The Food and Drug Administration Thursday expanded the approval of the drug Rituxan to treatcertain patients with chronic lymphocytic leukemia, a type of blood cancer.
|
|
|
Medical News: FDA Approves Rituxan To Treat Chronic Lymphocytic Leukemia
The U.S.Food and Drug Administration approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer. Medical News: FDA Approves Rituxan To Treat Chronic ...
|
|
|
Rituxan anti-cancer drug receives FDA approval
FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia The U.S.Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and...
|
|
|
FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia
-- Approval Based on Data From Two of the Largest Trials Ever Conducted in Chronic Lymphocytic Leukemia -- Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today...
|
|
|
FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia
-- Approval Based on Data From Two of the Largest Trials Ever Conducted in Chronic Lymphocytic Leukemia -- SOUTH SAN FRANCISCO, Calif.& CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genentech, Inc., a wholly owned member of the Roche Group (SIX:...
|
|
|
FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia
-- Approval Based on Data From Two of the Largest Trials Ever Conducted in Chronic Lymphocytic Leukemia -- SOUTH SAN FRANCISCO, Calif.& CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genentech, Inc., a wholly owned member of the Roche Group (SIX:...
|
|
|
FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia
-- Approval Based on Data From Two of the Largest Trials Ever Conducted in Chronic Lymphocytic Leukemia -- SOUTH SAN FRANCISCO, Calif.& CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 18, 2010 - Genentech, Inc., a wholly owned member of the...
|
|
|
FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia
Also News Release (U-BIIB) BIOGEN IDEC INC -- Approval Based on Data From Two of the Largest Trials Ever Conducted in Chronic Lymphocytic Leukemia -- Company Website: http://www.gene.com SOUTH SAN FRANCISCO, Calif.& CAMBRIDGE, Mass. -...
|
|
|
FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia
Also News Release (U-BIIB) BIOGEN IDEC INC -- Approval Based on Data From Two of the Largest Trials Ever Conducted in Chronic Lymphocytic Leukemia -- Company Website: http://www.gene.com SOUTH SAN FRANCISCO, Calif.& CAMBRIDGE, Mass. -...
|
|
|
FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia
-- Approval Based on Data From Two of the Largest Trials Ever Conducted in Chronic Lymphocytic Leukemia -- Buzz up!Companies: Related Quotes {"s" : "biib,rhhby.pk,ro.sw","k" : "c10,l10,p20,t10","o" : "","j" : ""} SOUTH SAN FRANCISCO, Calif!...
|
|
|
FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia
-- Approval Based on Data From Two of the Largest Trials Ever Conducted in Chronic Lymphocytic Leukemia -- SOUTH SAN FRANCISCO, Calif.& CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genentech, Inc., a wholly owned member of the Roche Group (SIX:...
|
|
|
FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia
Approval Based on Data From Two of the Largest Trials Ever Conducted in Chronic Lymphocytic Leukemia -- ) SOUTH SAN FRANCISCO, Calif.& CAMBRIDGE, Mass., Feb 18, 2010 (BUSINESS WIRE) -- Genentech, Inc., a wholly owned member of the Roche...
|
|
|
Rituxan Approved for Chronic Lymphocytic Leukemia
FRIDAY, Feb.19 (HealthDay News) -- Rituxan (rituximab) has been approved by the U.S. Food and Drug Administration to treat a slowly progressing form of blood and bone marrow cancer known as chronic lymphocytic leukemia (CLL), the agency said in...
National Womens Health Information Center:
Feb 19 2010 7:19PM
Matching: leukemia lymphocytic chronic
|
Find similar documents
|
|
|
|
Rituxan Approved for Chronic Lymphocytic Leukemia
FRIDAY, Feb.19 (HealthDay News) -- Rituxan (rituximab) has been approved by the U.S. Food and Drug Administration to treat a slowly progressing form of blood and bone marrow cancer known as chronic lymphocytic leukemia (CLL), the agency said in...
|
|
|
FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia
SILVER SPRING, Md., Feb.18 /PRNewswire-USNewswire/ The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer. ...
|
|
|
2/18/10 - FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia
SILVER SPRING, Md., Feb.18 /PRNewswire-USNewswire/ The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer. ...
|
|
|
FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia
SILVER SPRING, Md., Feb.18 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer....
|
|
|
FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia
ROCKVILLE, Md., Feb.18, 2010--The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer. Rituxan, an anti...
|
